Sym025

Symphogen has six immuno-oncology product candidates under development with Servier, of which three are currently in Phase 1 trials (Sym021, Sym022 and Sym023), one is in pre-clinical phase (Sym024), and two are in discovery phase (Sym025 and Sym026).

Currently, the majority of our research activities, both partnered and unencumbered, are in immuno-oncology and focused on identifying antibodies against novel targets to mobilize the immune system to fight tumors.